Which Endpoints Should We Use in Evaluating the Use of Novel Fluoropyrimidine Regimens in Colorectal Cancer?

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6600341
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC